AUDITED STATUTORY-BASIS FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. Years Ended December 31, 2018 and 2017 With Report of Independent Auditors and Independent Registered Public Accounting Firm

Ernst & Young LLP



Audited Statutory-Basis Financial Statements and Supplementary Information

Years Ended December 31, 2018 and 2017

Contents

Report of Independent Auditors	1
Report of Independent Registered Public Accounting Firm	3
Audited Statutory-Basis Financial Statements	
Statutory-Basis Balance Sheets	4
Statutory-Basis Statements of Operations	5
Statutory-Basis Statements of Changes in Surplus	
Statutory-Basis Statements of Cash Flow	7
Notes to Statutory-Basis Financial Statements	8
Supplementary Information	
Report of Independent Auditors on Supplementary Information	52
Investment Risk Interrogatories – Statutory Basis	
Summary of Investment Schedule – Statutory Basis	58
Note to Supplemental Investment Disclosures	60



Tel: +1 617 266 2000 Fax: +1 617 266 5843 ev.com

Report of Independent Auditors

The Board of Directors Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc.

We have audited the accompanying statutory-basis financial statements of Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. (the Company), which comprise the balance sheet as of December 31, 2018, and the related statements of operations, changes in capital and surplus and cash flow for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with accounting practices prescribed or permitted by the Commonwealth of Massachusetts Division of Insurance. Management also is responsible for the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles

As described in Note 2 to the statutory-basis financial statements, the Company prepared these financial statements using accounting practices prescribed or permitted by the Commonwealth of Massachusetts Division of Insurance, which is a basis of accounting other than U.S. generally accepted accounting principles. The effects on the financial statements of the variances between these statutory accounting practices and U.S. generally accepted accounting principles, although not reasonably determinable, are presumed to be material.

Adverse Opinion on U.S. Generally Accepted Accounting Principles

In our opinion, because of the significance of the matter described in the Basis for Adverse Opinion on U.S. Generally Accepted Accounting Principles paragraph, the statutory-basis financial statements referred to above do not present fairly, in conformity with U.S. generally accepted accounting principles, the financial position of the Company at December 31, 2018, or the results of its operations or its cash flows for the year then ended.

Opinion on Statutory-Basis of Accounting

In our opinion, the statutory-basis financial statements referred to above present fairly, in all material respects, the financial position of the Company at December 31, 2018, and the results of its operations and its cash flows for the year then ended, on the basis of accounting described in Note 2.

Ernst + Young LLP

April 26, 2019



working world

Tel: +1 617 266 2000 Fax: +1 617 266 5843 ey.com

Report of Independent Registered Public Accounting Firm

The Board of Directors Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc.

We have audited the accompanying statutory-basis balance sheets of Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. as of December 31, 2017, and the related statutory-basis statements of operations, changes in surplus and cash flow for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the auditing standards of the Public Company Accounting Oversight Board (United States) and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

As described in Note 2, the statutory-basis financial statements have been prepared in conformity with accounting practices prescribed or permitted by the Commonwealth of Massachusetts Division of Insurance, which practices differ from U.S. generally accepted accounting principles. The variances between such practices and U.S. generally accepted accounting principles are described in Note 2. The effects on the accompanying financial statements of these variances are not reasonably determinable but are presumed to be material.

In our opinion, because of the effects of the matter described in the preceding paragraph, the statutory-basis financial statements referred to above do not present fairly, in conformity with U.S. generally accepted accounting principles, the financial position of Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. at December 31, 2017, or the results of its operations or its cash flows for the year then ended.

However, in our opinion, the statutory-basis financial statements referred to above present fairly, in all material respects, the financial position of Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. at December 31, 2017, and the results of its operations and its cash flows for the year then ended in conformity with accounting practices prescribed or permitted by the Commonwealth of Massachusetts Division of Insurance.

Ernst + Young LLP

April 26, 2019

Statutory-Basis Balance Sheets (Dollars in Thousands)

	December 31			er 31
		2018		2017
Admitted assets				
Bonds	\$	891,299	\$	948,471
Common stock		211,118		187,671
Properties occupied by the Company		88,433		90,760
Cash, cash equivalents, and short-term investments		29,154		92,766
Receivable for securities		9,154		7,888
Other invested assets		921,886		952,189
Total cash and invested assets		2,151,044		2,279,745
Accrued investment income		4,542		4,679
Premiums receivable		34,683		46,258
Reinsurance recoverable		_		1,715
Data processing equipment		6,007		7,268
Health care receivables		55,539		65,106
Other receivables		13,539		2,650
Other assets		1,108		4,284
Total admitted assets	\$	2,266,462	\$	2,411,705
Liabilities and surplus				
Unpaid claims liabilities	\$	413,330	\$	402,230
Accrued medical incentive pool and bonus payments		54,362		97,458
Aggregate policy reserves		39,246		31,962
Premiums received in advance		134,863		110,201
Accounts payable and accrued liabilities		50,135		32,950
Federal income tax payable		213		_
Borrowed money		145,161		320,250
Amounts due to parent, subsidiaries, and affiliates		11,543		18,908
Payable for securities		3,854		14,082
Total liabilities		852,707		1,028,041
Special surplus funds		_		48,717
Unassigned surplus		1,413,755		1,334,947
Total surplus		1,413,755		1,383,664
Total liabilities and surplus	\$	2,266,462	\$	2,411,705

Statutory-Basis Statements of Operations (Dollars in Thousands)

	Year Ended 2018	December 31 2017		
Premiums earned	\$ 5,096,307	\$ 4,817,365		
Health care benefits	4,466,600	4,259,338		
Claims adjustment expenses	219,391	190,418		
General and administrative expenses	365,144	287,876		
Total expenses	5,051,135	4,737,632		
Underwriting gain	45,172	79,733		
Net investment income	48,372	37,111		
Net realized investment gains	491	3,897		
Net investment gains	48,863	41,008		
Other income	179	693		
Net income before federal income taxes	94,214	121,434		
Federal income tax expense	213			
Net income	\$ 94,001	\$ 121,434		

Statutory-Basis Statements of Changes in Surplus (Dollars in Thousands)

	Unassigned Surplus	Special Surplu Funds	ıs Total Surplus
	Surpius	runus	Suipius
Balance at December 31, 2016	\$ 1,207,684	\$ -	\$ 1,207,684
Net income	121,434	_	121,434
Change in net unrealized gains	59,451	_	59,451
Change in non-admitted assets	(4,905)) –	(4,905)
2018 ACA health insurer fee	(48,717)	48,717	
Balance at December 31, 2017	1,334,947	48,717	1,383,664
2018 ACA health insurer fee	48,717	(48,717)) –
Net income	94,001	_	94,001
Change in net unrealized gains	(60,910)) –	(60,910)
Change in non-admitted assets	(3,000)) –	(3,000)
Balance at December 31, 2018	\$ 1,413,755	\$ -	\$ 1,413,755

Statutory-Basis Statements of Cash Flow (Dollars in Thousands)

	Year Ended D 2018	ecember 31 2017
Operating activities		
Premiums received	\$ 5,140,931 \$	4,917,647
Health care benefits paid	(4,480,525)	(4,238,223)
General and claim adjustment expenses paid	(554,743)	(457,732)
Net investment income received	52,129	42,503
Net cash provided by operating activities	157,791	264,195
Investing activities		
Sales, maturities, and redemptions of investments	508,561	840,653
Cost of investments acquired	(517,877)	(1,095,380)
Net cash used in investing activities	 (9,316)	(254,727)
Financing or miscellaneous activities		
Borrowed funds	(175,000)	72,500
Other cash applications, net	(37,087)	(35,212)
Net cash (used in) provided by financing or miscellaneous		
activities	 (212,087)	37,288
Net (decrease) increase in cash, cash equivalents, and		
short-term investments	(63,612)	46,756
Cash, cash equivalents, and short-term investments:		
Beginning of year	92,766	46,010
End of year	\$ 29,154 \$	92,766

Notes to Statutory-Basis Financial Statements (Dollars in Thousands)

December 31, 2018

1. Nature of Business

Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. ("HMO Blue" or the "Company"), a wholly-controlled subsidiary of Blue Cross and Blue Shield of Massachusetts, Inc. ("BCBSMA"), is a Massachusetts nonprofit corporation organized under Chapter 180 of the Massachusetts General Laws ("M.G.L.") and holds a health maintenance organization license pursuant to Massachusetts General Laws Chapter 176G. HMO Blue and BCBSMA (collectively, the "Companies") operate under common management and Board of Directors control. The Company provides hospitalization, medical, and other health benefits to members through contracts with hospitals, participating physicians, skilled nursing facilities, nursing homes, and other health care providers and organizations. The Company offers a variety of HMO and other supplementary programs for the benefit of its members.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in accordance with the National Association of Insurance Commissioners ("NAIC") *Statements of Statutory Accounting Principles* ("SSAP"), and in conformity with accounting practices prescribed or permitted by the Commonwealth of Massachusetts Division of Insurance ("DOI"), which practices differ from US generally accepted accounting principles ("GAAP").

The more significant variances from GAAP are as follows:

Investments: Investments in bonds not backed by other loans are principally stated at amortized cost using the constant yield (interest) method. Bonds can also be stated at the lesser of amortized cost or fair value based on their NAIC designated rating. Preferred stocks are reported at lower of cost or fair value. The related net unrealized gains (losses) are reported in unassigned surplus. For GAAP, such fixed maturity investments would be designated as available-for-sale or held-for-trading and reported at fair value with unrealized investment gains and losses reported as a separate component of stockholder's equity for available-for-sale, unless the decline is believed to be other-than-temporary, or as earnings for held-for-trading.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Fair value for statutory purposes, as with GAAP, is based on quoted market prices while the fair value of private placements and credit tenant loans is obtained from independent third-party dealers.

The Company has a process in place to identify bonds, excluding loan-backed and structured securities that could potentially have an impairment that is other-than-temporary. For statutory reporting, the Company recognizes other-than-temporary impairment losses on bonds with unrealized losses when either of the following two conditions exist: the Company either (1) has the intent to sell the debt security or (2) is more likely than not to be required to sell the debt security before its anticipated recovery. Declines in value due to credit difficulties are also considered to be other-than-temporarily impaired when the Company does not have the intent and ability to hold the security for a period of time sufficient to allow for any anticipated recovery in value. For statutory reporting, the entire difference between amortized cost and fair value on such bonds with credit difficulties is recognized as an impairment loss in earnings. For GAAP, an impairment loss is recognized in earnings determined as the difference between amortized cost and the net present value of the projected future cash flows discounted at the effective interest rate implicit in the debt security prior to impairment. The remaining difference between the net present value and the fair value is recognized as a non-credit unrealized loss in accumulated other comprehensive income for GAAP.

All single class and multi-class mortgage-backed or asset-backed securities (i.e. collateralized mortgage obligations) are adjusted for the effects of changes in prepayment assumptions on the related accretion of discounts or amortization of premiums of such securities using either the retrospective or prospective methods. The retrospective adjustment method is used to value all such securities, except principal-only and interest-only securities and such securities with NAIC designations of 3 through 6, which are valued using the prospective method. If it is determined that a decline in fair value is other-than-temporary, the cost basis of the security is written down to the present value of estimated future cash flows using the original effective interest rate inherent in the security.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

For GAAP, all securities purchased or retained that represent beneficial interests in securitized assets (i.e. asset-backed securities, including collateralized mortgage obligations, collateralized bond obligations, collateralized debt obligations, collateralized loan obligations, and mortgage-backed securities) and other than high credit quality securities with fixed rates of interest are carried at fair value, and their rate of income recognition is adjusted using the prospective method when there is a change in estimated future cash flows.

If it is determined that an other-than-temporary credit impairment has occurred, the security is written down through earnings to the present value of estimated future cash flows using the original effective interest rate inherent in the security, with any further non-credit impairment recorded in the accumulated other comprehensive income to adjust the investment to its current fair value. This non-credit portion of the impairment recorded for GAAP is not recognized under NAIC guidelines. High credit quality asset-backed securities with fixed rates of interest are also carried at fair value for GAAP, but if their estimated future cash flows change, the retrospective method is used.

Investments in real estate are reported net of related obligations rather than on a gross basis. Real estate owned and occupied by the Company is included in investments rather than reported as an operating asset under GAAP, and investment income and operating expenses include rent for the Company's occupancy of those properties.

Non-admitted Assets: Certain assets designated as "non-admitted," including furniture, fixtures and equipment, leasehold improvements, non-operating system software, prepaid expenses, certain premium receivable balances, and other assets not specifically identified as an admitted asset within the SSAP, are excluded from the accompanying balance sheets and are charged directly to surplus. Under GAAP, such assets are included in the balance sheets, net of any impairment charge.

Statements of Cash Flow: Cash, cash equivalents, and short-term investments in the statements of cash flow represent cash balances and investments with initial maturities of one year or less. Under GAAP, the corresponding caption of cash and cash equivalents includes cash balances and investments with initial maturities of three months or less.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

The effects of the foregoing variances from GAAP on the accompanying statutory-basis financial statements have not been determined, but are presumed to be material.

Other significant accounting practices are as follows:

Use of Estimates

The preparation of the financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Investments

Investments are stated at values prescribed by the NAIC, as follows:

Investments in bonds not backed by other loans are principally stated at amortized cost using the constant yield (interest) method. Bonds can also be stated at the lesser of amortized cost or fair value based on their NAIC designated rating.

Common stock is stated at fair value.

The Company has various ownership interests in limited liability partnerships and limited liability companies. The Company carries these investments based on its ownership interest in the underlying GAAP equity of the investee. These investments are included as other invested assets on the balance sheets.

Unrealized gains and losses on common stock and other invested assets are reflected directly in surplus unless there is deemed to be an other-than-temporary decline in value, in which case the loss is charged to income. Realized gains and losses on investments sold are determined using the specific identification method and are included in income.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Amortization of bond premium and accretion of bond discount are recognized on a yield-basis method. Security transactions are accounted for on a trade-date basis, with any unsettled transactions recorded as due to or from investment broker and included as payable or receivable for securities in the balance sheets.

Investment income is recognized as income when earned. Accrued investment income is defined as investment income earned as of the reporting date, but not legally due to be paid to the Company until subsequent to the reporting date.

Cash equivalents are short-term highly liquid investments with original maturities of three months or less and are principally stated at amortized cost. Short-term investments include investments with remaining maturities of one year or less at the time of acquisition and are principally stated at amortized cost.

Real Estate

Land is recorded at cost, and other real estate, which includes expenditures for significant improvements, is recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life (typically 50 years).

The Companies jointly own land and buildings with 349,058 square feet of office space in Quincy, Massachusetts and 328,945 square feet of office space in Hingham, Massachusetts.

The components of the Company's real estate are summarized as follows:

	December 31					
	 2018		2017			
Land and buildings Less accumulated depreciation	\$ 115,288 (26,855)	\$	115,428 (24,668)			
Net real estate occupied by the Company	\$ 88,433	\$	90,760			

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Under statutory reporting guidelines, the Companies are required to calculate imputed rental income for owner-occupied real estate. The method for calculating imputed rental income is based on estimated rental rates of like property in the same area multiplied rentable square feet. These imputed amounts are reported as net investment income and general and administrative expenses in the statements of operations reflecting that the Company had recorded annual rent of \$6,058 for December 2018 and 2017.

Furniture, Equipment, and Capitalized Software

The admitted value of the Company's electronic data processing equipment ("EDP") and operating software is limited to three percent of adjusted surplus. The Company's admitted portion is reported at cost, less accumulated depreciation.

The components of the Company's EDP and operating software are summarized as follows:

	December 31				
		2018	2017		
EDP equipment and operating software Less accumulated depreciation	\$	49,170 \$ (43,163)	46,879 (39,611)		
Net EDP equipment and operating software	\$	6,007 \$	7,268		

The Company calculates depreciation on furniture, equipment, and leasehold improvements and amortization of capitalized software using the straight-line method. Furniture and equipment is depreciated over its estimated useful life or ten years; leasehold improvements over the lesser of its useful life or the term of the lease; operating software over the lesser of its useful life or three years; and internally developed software over the lesser of its useful life or five years.

Depreciation and amortization expense charged to income in 2018 and 2017 was \$16,330 and \$19,784, respectively.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

The Company continually evaluates the recoverability of long-lived assets by assessing whether the carrying amount of asset balances can be recovered as measured against the future undiscounted net cash flows expected to be generated by the assets. The future undiscounted net cash flows are based on historical trends, revenue forecasts, and market trends projected over the remaining life of the long-lived assets.

If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. In 2018 and 2017, the Company did not have any impairment expenses.

Unpaid Claims Liabilities

The Company uses estimates for determining its claims incurred but not yet reported which are based on historical claim payment patterns, healthcare trends and membership, and includes a provision for adverse changes in claim frequency and severity. Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled.

Liabilities at any year end are continually reviewed and re-estimated as information regarding actual claims payments become known. This information is compared to the originally established year end liability.

Management believes its methodologies for reserving for unpaid claims are appropriate and represent its best estimate.

Accrued Medical Incentive Pool and Bonus Payments

Medical incentive pools and bonus accruals represent the liability for risk sharing arrangements with health care providers where the Company agrees to share savings with contracted providers.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Aggregate Policy Reserves

Aggregate policy reserves represent a reserve for unearned premium income, rate credits, experience rating refunds, ACA risk adjustment and medical loss ratio rebates.

Premium Deficiency

The Company evaluates its health care contracts to determine if it is probable that a loss will be incurred. A premium deficiency loss is recognized when it is probable that expected future paid claims, administrative expenses, and reserves will exceed existing reserves plus anticipated future premiums on existing contracts. Anticipated investment income and overhead expenses are also considered in the calculation of premium deficiency losses. As of December 31, 2018 and 2017, the Company did not have a premium deficiency reserve.

Premiums

The Company receives premium revenue from insured business. Member premiums are billed in advance of their respective coverage periods. Premium receivables are recorded when due. Premium earned is recorded during the coverage period. Aggregate policy reserves are established to cover the unexpired portion of premiums written and are computed by pro-rata methods for direct business.

Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to administrative expenses as incurred. The premium paid by subscribers prior to the effective date is recorded in the balance sheet as premiums received in advance and subsequently credited to income as earned during the coverage period.

The provisions of the Patient Protection and Affordable Care Act ("PPACA" or "ACA") and implementing regulations require commercial health plans with a medical loss ratio ("MLR") on fully insured products that fall below certain targets to rebate ratable portions of their premiums annually. The Company's management thereby regularly monitors MLR calculations by market type and records the applicable liability and expense if the MLR falls below the minimum requirements pursuant to the PPACA.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

For uncollected premium, after the calculation of non-admitted amounts, an evaluation is made of the remaining admitted assets in accordance with SSAP No. 5, *Liabilities, Contingencies and Impairment of Assets*, to determine if there is a collectability issue.

If it is probable that the balance is uncollectible, any uncollectible amount is written off and charged to income in the period the determination is made. In 2018 and 2017, the amount charged to income was \$325 and \$487, respectively.

Affordable Care Act ("ACA")

Effective January 1, 2014, the Company adopted Statement of Statutory Accounting Principles No. 106, *Affordable Care Act Assessments* ("SSAP 106"). SSAP 106 provides accounting treatment for the assessment under Section 9010 of the Patient Protection and Affordable Care Act (ACA) of entities issuing health insurance. Refer to Note 20.

Effective January 1, 2014, the Company also adopted SSAP No. 107, *Accounting for the Risk-Sharing Provisions of the Affordable Care Act* ("SSAP 107"). The Affordable Care Act ("ACA") imposes fees and premium stabilization provisions on health insurance issuers offering commercial health insurance. The risk-sharing provisions include three programs known as risk adjustment, reinsurance, and risk corridor. The required payments to the programs are reported as assessments and amounts distributed back to the insurance companies are presented as recoverable or receivable on the balance sheet. Refer to Note 13.

The risk adjustment program based on Section 1343 of the ACA is effective beginning in the 2014 benefit year and continues as a permanent program. The risk adjustment program includes health plans participating in the state individual or small group markets. The purpose of the risk adjustment program is to transfer funds from lower risk plans to higher risk plans in the same state in order to adjust premiums for adverse selection among carriers caused by membership shifts due to guarantee issue and community rating mandates.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

The Company takes part in the federal risk adjustment program whereby premium adjustments are based on the risk scores of enrollers rather than the actual loss experience of the insured. The risk adjustment payables and receivables are accounted for as premium adjustments subject to redetermination.

In addition to the risk adjustment amount, the federal government determines the user fee, which is treated as an assessment and recognized as an expense and liability when the premium subject to assessment is earned.

The transitional or temporary reinsurance program based on Section 1341 of the ACA was effective for plan years 2014 through 2016. Reinsurance assessments were collected and distributions have been issued during this three-year term. In general, this transitional reinsurance program provided funding to issuers in the individual market that incur high claims costs for enrollees. The program required assessments from all issuers based on a per member annual fee established by the Department of Health and Human Services ("HHS"). The reinsurance program for individual insured products was accounted for as a traditional reinsurance program with assessments reported as ceded premium and distributions received for the reimbursement of claims reflected as ceded claim benefits recovered.

The risk corridor program based on Section 1342 of the ACA was effective for benefit years 2014 through 2016. The risk corridors program applied to Qualified Health Plans ("QHPs") in the individual and small group markets. If applicable, any risk corridor payable or receivable was reported as a component of accounts receivable, and was included in other receivables on the balance sheets. Any related expense or revenue associated with the risk corridor program was included as a component of premiums earned on the statements of operations.

The three year reinsurance and risk corridor programs ended on December 31, 2016. It was assumed that over this three year period, insurers would gain more familiarity with enrollees and would be able to price their products with greater certainty. These temporary ACA programs were intended to protect against negative effects of adverse selection and risk selection, and also work to stabilize premiums during the initial implementation years of the ACA. Any adjustments or outstanding balances related to these programs are included in the 2018 and 2017 financial results.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Health Care Receivables

The Company enters into contractual agreements with various health care providers to provide certain medical services to its members. Compensation arrangements vary by provider. Certain providers have entered into risk-sharing arrangements with the Company, whereby a settlement is calculated by comparing actual medical claims experience to a pre-approved and predetermined budgeted amount. These settlements are accrued on an estimated basis in the period the related services are rendered, and adjusted in future periods as final settlements are determined. Estimated settlements for these risk-sharing arrangements are reflected in health care receivables on the Company's balance sheets.

Other amounts included in health care receivables represent pharmaceutical rebates, claims overpayments, advances to the providers and capitation arrangement receivables. Pharmaceutical rebates are arrangements with pharmaceutical companies negotiated by the Company's pharmacy benefit manager ("PBM"), in which the Company receives rebates based upon certain drug utilization of its subscribers. Claim overpayments occur as a result of several events, including, but not limited to, claim payments made in error to a provider. The Company also makes advances to providers when those advances are supported by legally enforceable contracts and are generally entered into at the request of the providers.

Advances to the providers under a capitation arrangement are usually made in anticipation of future services, and used in connection with some managed care contracts, when a physician or other medical provider is paid a flat amount.

Fair Value of Financial Instruments

The fair value of investment securities is estimated based on quoted prices for those or similar investment securities. The carrying amounts of cash, cash equivalents and short-term investments approximate fair value because of the short maturity of these instruments.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

2. Summary of Significant Accounting Policies (continued)

Recent Accounting Pronouncements

In March 2017, the NAIC made substantive revisions to SSAP No. 69 – *Statement of Cash Flow* to adopt ASU 2016-15 *Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments* as issued by the FASB, without modifications. The revisions clarified the classification of eight specific cash flow issues with the objective of reducing diversity in practice. The amendment is to be applied retrospectively, effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. The Company will adopt the amendment in 2019 and is currently assessing the impact of these revisions on its financial statements.

In August 2017, the NAIC adopted non-substantive revisions to SSAP No. 69 – *Statement of Cash Flow* to adopt ASU 2016-18 *Statement of Cash Flows: Restricted Cash* as issued by the FASB. The revision clarifies that restricted cash and cash equivalents shall not be reported as operating, investing or financing activities, but shall be reported with cash and cash equivalents when reconciling beginning and ending amounts on the cash flow statement. A consequential change was incorporated in SSAP No. 1 – *Accounting Policies, Risks & Uncertainties and Other Disclosures* to ensure information on restricted cash, cash equivalents and short-term investments is reported in the restricted asset disclosure. The revision is effective December 31, 2019, to be adopted retrospectively to allow for comparative cash flow statements. Early adoption is permitted. The Company will adopt the amendment in 2019 and is currently assessing the impact of these revisions on its financial statements.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments

Included in various investment related line items in the financial statements are certain financial instruments carried at fair value. Fair values are based on quoted market prices when available. When market prices are not available, fair value is generally estimated by incorporating current market inputs for similar financial instruments. In instances where there is little or no market activity for the same or similar instruments, the Company estimates fair value using methods, models, and assumptions that management believes market participants would use to determine a current transaction price.

The Company's statutory-basis financial assets have been classified, for disclosure purposes, based on a hierarchy defined by SSAP No. 100R, *Fair Value Measurement* ("SSAP 100R"). The levels of the fair value hierarchy are as follows:

Level 1 – Values are unadjusted quoted prices for identical assets in active markets accessible at the measurement date.

Level 2 – Inputs include quoted prices for similar assets in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are observable or can be corroborated by market data for the term of the instrument. Such inputs include market interest rates and volatilities, spreads, and yield curves.

Level 3 – Certain inputs are unobservable (supported by little or no market activity) and significant to the fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset at the reporting date.

Investments in mutual funds are carried at estimated fair value based on quoted market prices and are recorded in the statutory-basis balance sheets as common stock. These assets include primarily actively-traded exchange-listed mutual funds identified as common stock. Unadjusted quoted prices for these securities are provided to the Company by independent pricing services.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

Level 2 assets consist primarily of bonds, including U.S. government, industrial, and miscellaneous, mortgage backed securities, and preferred stocks which are valued using pricing models with observable market inputs.

Level 3 investments include holdings in real estate investment trusts ("REITs") and other privately issued stock holdings. Fair values of the REIT holdings are provided to the Company by the trust manager either monthly or quarterly and are derived from limited observable inputs as a result of low transaction volume. The Company also holds privately issued common stocks that experience similarly low transaction volume. The Company obtains prices for these investments quarterly and considers these prices to approximate fair value.

The Company reviews the fair value hierarchy classifications each reporting period. Changes in the observability of the valuation attributes may result in a reclassification of certain financial assets. Such reclassifications are reported as transfers in and out of Level 3, or between other levels, at the ending fair value for the reporting period in which the changes occur. There were no significant transfers between levels for the year ended December 31, 2018.

Investments in partnerships and similar investments are recorded in the statutory-basis balance sheets as other invested assets. Other invested asset investments in subsidiary, controlled, and affiliated entities are recorded using the statutory equity method. These investments are not included within the scope of SSAP 100R.

As of December 31, 2018 and 2017, included in the Company's Other Invested Assets is an investment in a surplus note, issued by BCBSMA with a carrying value of \$280,749 and \$285,000, respectively.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

The following table presents the Company's financial assets that are measured and reported at fair value in the balance sheets by fair value hierarchy level at December 31, 2018 and 2017:

	December 31, 2018								
Description		Level 1	Level 2		Level 3		Total		
Bonds:									
Industrial and miscellaneous	\$	- \$	2,405	\$	_	\$	2,405		
Common stock:									
Industrial and miscellaneous		143,572	_		67,276		210,848		
Parent, subs, and affiliates			_		270		270		
Total assets at fair value	\$	143,572 \$	2,405	\$	67,546	\$	213,523		

		Decembe	er 31, 2017	
Description	Level 1	Level 2	Level 3	Total
Common stock:				
Industrial and miscellaneous	\$ 124,959	\$ -	\$ 62,461 \$	187,420
Parent, subs, and affiliates		_	251	251
Total assets at fair value	\$ 124,959	\$ -	\$ 62,712 \$	187,671

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

Fair Value Measurements in Level 3:

			Total Gain Included in Net Realized	Total (Losses)				
	Balance at January 1, 2018	s Transfers out Level 3		Included in Surplus	Purchases	Sales	Issuances and Settlements	Balance at December 31, 2018
Common stock Industrial and miscellaneous Parent, subs, and affiliates Total assets	\$ 62,461 251 \$ 62,712	 - \$ - 5 -	<u> </u>	\$ 2,927 19 \$ 2,946	\$ 1,888 - \$ 1,888		* \$ — - — * \$ —	\$ 67,276 270 \$ 67,546

	Balance at January 1,	in	out	Gains and	Total (Losses) Included in				Balance at December 31,
	2017	Level 3	Level 3	(Losses)	Surplus	Purchases	Sales	Settlements	2017
Common stock									
Industrial and miscellaneous	\$ 60,485	\$ -	\$ -	\$ 161	\$ 1,701	\$ 275 5	(161)) \$ -	\$ 62,461
Parent, subs, and affiliates	236	_	_	_	15	_	_	_	251
Total assets	\$ 60,721	\$ -	\$ -	\$ 161	\$ 1,716	\$ 275 5	(161)) \$ _	\$ 62,712

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

The table below presents the fair value by hierarchy level for certain financial assets that are not reported at fair value in the balance sheets:

	December 31, 2018							
Description	Le	vel 1		Level 2	I	Level 3		Total
Bonds:								
U.S. treasury securities	\$	_	\$	257,815	\$	_	\$	257,815
Industrial and miscellaneous		_		312,548		_		312,548
Mortgage-backed securities				304,192				304,192
Total	\$	_	\$	874,555	\$	_	\$	874,555

	December 31, 2017									
Description	Le	vel 1		Level 2	L	evel 3		Total		
Bonds:										
U.S. treasury securities	\$	_	\$	305,404	\$	_	\$	305,404		
Industrial and miscellaneous		_		343,199		_		343,199		
Mortgage-backed securities		_		300,178		_		300,178		
Total	\$	_	\$	948,781	\$	_	\$	948,781		

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

The cost or amortized cost, gross unrealized gains, gross unrealized losses, and fair value of cash and investments are as follows:

	December 31, 2018									
		Cost or		Gross		Gross				
	A	Amortized	J	J nrealized	ι	Inrealized	Fair			
		Cost		Gains		Losses	Value			
Cash, cash equivalents, and										
short-term investments	\$	29,154	\$	_	\$	- \$	29,154			
Bonds:										
U.S. treasury securities and agency										
obligations		261,586		865		(4,636)	257,815			
Industrial and miscellaneous		318,336		1,680		(7,468)	312,548			
Mortgage-backed securities		311,377		951		(8,136)	304,192			
Total bonds		891,299		3,496		(20,240)	874,555			
Common stock		187,455		27,209		(3,546)	211,118			
Total cash and investments	\$	1,107,908	\$	30,705	\$	(23,786) \$	1,114,827			

			Decemb	er :	31, 2017	
	 Cost or Amortized	τ	Gross Inrealized	Į	Gross Unrealized	Fair
	 Cost		Gains		Losses	Value
Cash, cash equivalents, and						
short-term investments	\$ 92,766	\$	_	\$	- \$	92,766
Bonds:						
U.S. treasury securities and agency						
obligations	306,872		909		(2,377)	305,404
Industrial and miscellaneous	339,319		5,713		(1,833)	343,199
Mortgage-backed securities	302,280		1,344		(3,446)	300,178
Total bonds	948,471		7,966		(7,656)	948,781
Common stock	 150,826		36,916		(71)	187,671
Total cash and investments	\$ 1,192,063	\$	44,882	\$	(7,727) \$	1,229,218

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

At December 31, 2018 and 2017, there are no bonds that are non-admitted due to a default or near default status.

The following tables show gross unrealized losses and fair values of bonds and equities and length of time that individual securities have been in a continuous unrealized position.

At December 31, 2018
U.S. treasury securities
Industrial and miscellaneous
Mortgage-backed securities
Total Bonds
Common stock
Total

Less than	12 N	Ionths	12 Month	ıs or	More	Te			
		Gross			Gross			Gross	
Fair	Uı	ırealized	Fair	U	nrealized	Fair	U	nrealized	Number of
 Value		Losses	Value		Losses	Value		Losses	Securities
\$ 34,669	\$	(318)	\$ 160,510	\$	(4,318)	\$ 195,179	\$	(4,636)	78
106,074		(2,194)	155,573		(5,274)	261,647		(7,468)	552
25,332		(325)	213,690		(7,811)	239,022		(8,136)	369
166,075		(2,837)	529,773		(17,403)	695,848		(20,240)	999
29,126		(2,314)	15,045		(1,232)	44,171		(3,546)	3
\$ 195,201	\$	(5,151)	\$ 544,818	\$	(18,635)	\$ 740,019	\$	(23,786)	1,002

At December 31, 2017 U.S. treasury securities Industrial and miscellaneous Mortgage-backed securities Total Bonds Common stock

 Less than	12 N	Months		12 Month	ıs or	More		Total			
Fair Value	U			Fair Value	Gross Unrealized Losses			Fair Value	τ	Gross Inrealized Losses	Number of Securities
\$ 209,391 65,643 84,919	\$	(1,684) (388) (569)	\$	41,999 94,957 143,804	\$	(694) (1,444) (2,877)	\$	251,390 160,600 228,723	\$	(2,378) (1,832) (3,446)	89 260 389
 359,953 1,122		(2,641) (71)		280,760		(5,015)		640,713 1,122		(7,656) (71)	738 3
\$ 361,075	\$	(2,712)	\$	280,760	\$	(5,015)	\$	641,835	\$	(7,727)	741

In accordance with SSAP No. 2R—Cash, Cash Equivalents, Drafts, and Short-Term Investments, all money-market mutual funds ("MMMF's") are classified as cash equivalents effective December 31, 2017, and on a prospective basis. As of December 31, 2018 and 2017, the Company's investments in MMMF's of \$18,124 and \$22,083, respectively, are included in cash, cash equivalents and short-term investments.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

Management regularly reviews the fair value of the Company's investments. If the fair value of any investment falls below its cost basis, the decline is analyzed to determine whether the decline in value is other-than-temporary. To make this determination for each security, the following is considered:

- The length of time and the extent to which the fair value has been below cost;
- The financial condition and near-term prospects of the issuer of the security, including any specific events that may affect its operations or earnings potential;
- Volatility inherent in the asset class to which the investment belongs;
- Management's intent and ability to hold the respective securities long enough for it to recover its value.

At December 31, 2018 and 2017, included in the Company's investments are unrealized losses deemed to be temporary. These investments reflect a range of industries, and the Company determined the current market volatility is temporary.

In 2018 and 2017, the Company did not record any other-than-temporary impairments.

The amortized cost and fair value of bonds at December 31, 2018, by stated maturity, are shown below. Fixed maturities subject to early or unscheduled prepayments have been included based upon their stated maturity dates. Actual maturities may differ from stated maturities because borrowers have the right to call or prepay obligations with or without call or prepayment penalties.

	Cost or mortized Cost	Fair Value
Within 1 year After 1 year through 5 years After 5 years through 10 years After 10 years Total bonds	\$ 24,367 296,158 171,982 398,792 891,299	\$ 24,236 290,970 169,984 389,365 874,555

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

Proceeds, realized gains and losses from investment securities sales are as follows:

	Proceeds	Proceeds from Sales					Realized Losses			
Description	2018	2017		2018		2017		2018	2017	
Bonds	\$ 447,588	\$ 644,789		1,511	\$	4,058	\$ (4,042)		(3,848)	
Common stock	_	37,200		_		2,714		_	_	
Other invested assets	60,808	155,207		3,916		1,433		(836)	(526)	

Gross realized investment gains and losses are as follows:

	 2018	2017
Gross gains Gross losses	\$ 5,455 \$ (4,964)	8,278 (4,381)
Net realized investment gains	\$ 491 \$	3,897

Major categories of net investment income are summarized as follows:

	 2018	2017
Income:		
Bonds	\$ 24,308 \$	19,912
Other invested assets	20,045	14,470
Common stock	10,984	8,633
Preferred stock	_	23
Real estate	6,058	6,058
Cash, cash equivalents and short-term investments	1,465	1,243
Other miscellaneous	 606	3,043
Total investment income	63,466	53,382
Less: investment expenses	12,907	14,051
Depreciation	 2,187	2,220
Net investment income	\$ 48,372 \$	37,111

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

3. Cash and Investments (continued)

As of December 31, 2018, the Company had the following structured notes:

CUSIP Identification		Actual Cost		Fair Value		Book/ Adjusted Carrying Value	Mortgage- Referenced Security (Yes/No)
	_		_		_		
912810-RF-7	\$	1,767	\$	1,747	\$	1,839	No
912828-K3-3		9,875		10,144		10,406	No
912828-NM-8		8,134		8,128		8,290	No
912828-PP-9		8,277		8,343		8,543	No
912828-QV-5		9,411		9,369		9,679	No
912828-SA-9		10,193		10,221		10,562	No
Total	\$	47,657	\$	47,952	\$	49,319	

4. Restricted Assets

The Company's restricted assets and pledged collateral are summarized in the table as follows:

		2018		2017				2018
		Total		Total				Total
		Gross		Gross]	Increase/	A	Admitted
	R	Restricted	F	Restricted]	Decrease	R	Restricted
Restricted assets category								
Federal Home Loan Bank ("FHLB")								
capital stock	\$	6,375	\$	6,375	\$	_	\$	6,375
Pledged as collateral to FHLB		114,190		112,150		2,040		114,190
On deposit with states ^(a)		1,143		1,142		1		1,143
Other restricted assets ^(b)		8,967		6,333		2,634		760
Total	\$	130,675	\$	126,000	\$	4,675	\$	122,468

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

4. Restricted Assets (continued)

- (a) At December 31, 2018 and 2017, HMO Blue had restricted securities, included in bonds, and on deposit with the Commonwealth of Massachusetts as required by M.G.L. c.176G, section 26.
- (b) At December 31, 2018 and 2017, BCBSMA had Commonwealth of Massachusetts Tax Credits as restricted assets included in other assets on the statutory-basis balance sheets.

5. Health Care Benefits, Net of Reinsurance

The Company's health care benefits are summarized in the reconciliation of the beginning and ending balances of the unpaid claims liability, net of recoveries, health care receivables and accrued medical incentive pool and bonus payments are as follows:

					2018				
						N	Aedical		_
	Unpaid					Ir	icentive		
	Claims	Re	insurance	H	eath Care	P	ool and	T	otal Health
	 Liability	Re	coverable	R	eceivable		Bonus	Ca	are Benefits
Net balance at January 1 Incurred related to:	\$ 402,230	\$	(1,715)	\$	(82,526)	\$	97,458	\$	415,447
Current year	4,516,375		_		(136,252)		152,598		4,532,721
Prior years	(36,216))	(1,101)		(26,051)		(2,753)		(66,121)
Total incurred	4,480,159		(1,101)		(162,303)		149,845		4,466,600
Paid related to:									
Current year	4,110,014		_		(78,199)		106,166		4,137,981
Prior years	359,045		(2,816)		(100,460)		86,775		342,544
Total paid	4,469,059		(2,816)		(178,659)		192,941		4,480,525
Net balance at December 31	\$ 413,330	\$	_	\$	(66,170)	\$	54,362	\$	401,522

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

5. Health Care Benefits, Net of Reinsurance (continued)

		2017									
	Unpaid Claims Liability	Reinsurance Recoverable	Heath Care Receivable	Medical Incentive Pool and Bonus	Total Health Care Benefits						
Net balance at January 1 Incurred related to:	\$ 381,169	\$ (13,611)	\$ (47,178)	\$ 73,953	\$ 394,333						
Current year	4,308,739	_	(153,989)	182,021	4,336,771						
Prior years	(27,767)	(6,432)	(20,627)	(22,607)	(77,433)						
Total incurred	4,280,972	(6,432)	(174,616)	159,414	4,259,338						
Paid related to:											
Current year	3,919,347	_	(86,086)	88,763	3,922,024						
Prior years	340,564	(18,328)	(53,182)	47,146	316,200						
Total paid	4,259,911	(18,328)	(139,268)	135,909	4,238,224						
Net balance at December 31	\$ 402,230	\$ (1,715)	\$ (82,526)	\$ 97,458	\$ 415,447						

Negative amounts reported for incurred related to prior years result from claims being settled for amounts less than originally estimated. The favorable development in medical claims payables for the years ended December 31, 2018 and 2017, is primarily attributable to actual claim payment patterns and cost trends differing from those assumed at the time the liability was established.

At December 31, 2018 and 2017, health care receivables include \$10,631 and \$17,420, respectively, of amounts that are non-admitted in accordance with SSAP No. 84, *Certain Health Care Receivables and Receivables Under Government Insured Plans*.

Management believes its methodologies for reserving for unpaid claims are appropriate and represent its best estimate at December 31, 2018 and 2017. Estimated subrogation credits of \$7,022 and \$6,111 were taken into account in determining health care benefits reserves as of December 31, 2018 and 2017, respectively.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

6. Pension and Other Post-Retirement Benefit Plans

The pension and other post-retirement benefit plans ("Plans") are sponsored by BCBSMA and the associated costs are shared by the Companies. BCBSMA allocates amounts to the Company and wholly owned subsidiaries based on salary ratios. All employees who have completed twelve months of employment are eligible to participate in BCBSMA's Retirement Income Trust Plan ("RIT"), which grants benefits to retired employees at various levels based on age and years of service. BCBSMA also participates in two noncontributory retirement plans for eligible employees. BCBSMA uses a December 31 measurement date for all of its plans. The Company is an active participating employer of the Plans.

Since 2016, HMO Blue uses a spot rate approach to determine service cost and interest cost. BCBSMA's actuarial basis for discount rate determination is the Mercer Select 100 Yield Curve.

The Company's share of the net expenses for the years ended December 31, 2018 and 2017, are as follows:

	Pension Benefits			Post-Retirement Benefits		Postemployment and Compensated Absences						
		2018		2017		2018		2017		2018		2017
Service cost	\$	4,700	\$	6,004	\$	1,094	\$	1,106	\$	20,313	\$	17,769
Interest cost		6,650		9,180		1,423		1,766		· _		_
Expected return on plan assets		(14,320)		(17,382)		(1,819)		(1,899)		_		_
Amortization of unrecognized												
transitional obligation		159		162		_		_		_		_
Recognized actuarial loss		5,184		7,167		_		_		_		_
Amortization of prior service cost		(16)		(23)		672		820		_		_
Amount of loss recognized due												
to settlement		_		1,027		_		_		_		_
Total net periodic benefit cost	\$	2,357	\$	6,135	\$	1,370	\$	1,793	\$	20,313	\$	17,769

The Companies do not have any regulatory contribution requirements for 2019. However, the Companies currently intend to make voluntary contributions of \$45,000 to its defined benefit pension plan and \$4,909 to its post-retirement benefit plan in 2019.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

6. Pension and Other Post-Retirement Benefit Plans (continued)

The Companies other post-retirement benefit plan includes medical, dental, and life benefits for retired employees. The plan is funded by a 401(h) account. The Companies made a contribution into this account of \$5,308 and \$5,634 in 2018 and 2017, respectively. Total employer contributions to the post-retirement benefit plan were \$8,175 and \$8,714 in 2018 and 2017, respectively.

BCBSMA also has a 401(k) savings plan for eligible employees. Under the employee savings plan, BCBSMA contributes an amount equal to 100% of employee contributions, up to a maximum of 4% of each employee's compensation, subject to Internal Revenue Service limits of \$55 and \$54 for 2018 and 2017, respectively. The Company's allocated costs for the 401(k) plan were \$6,833 and \$6,603 in 2018 and 2017, respectively. In 2018, the Company continued to make an additional core contribution of 2% of base pay for all associates subject to the Internal Revenue Code limit.

7. Income Taxes

The Company is reporting as an organization exempt from federal income taxes under Internal Revenue Code Section 501(c)(4), and is exempt from Massachusetts state income taxes.

The Company would be required to adopt Accounting Standards Codification No. 740-10, Income Taxes ("ASC 740"), Accounting for Uncertainty in Income Taxes, if it prepared GAAP-basis financial statements for the years ended December 31, 2018 and 2017. This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Similar guidance has not been adopted by the NAIC. If the Company were to adopt ASC 740 for statutory reporting purposes, it would have no impact on the financial statements.

The Company files income tax returns in the US federal jurisdiction. The Company's open tax years are 2015 through 2018. The Company would recognize any interest and penalties resulting from ASC 740 in general and administrative expenses.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

7. Income Taxes (continued)

The Tax Cuts and Jobs Act ("TCJA") was enacted on December 22, 2017. For tax-exempt entities, the TCJA requires organizations to categorize certain fringe benefit expenses as a source of unrelated business income, pay an excise tax on remuneration above certain thresholds that is paid to executives by the organization, and report income or loss from unrelated business activities on an activity-by-activity basis and other provisions. The provision for these taxes at December 31, 2018 is \$213.

8. State Transferable Tax Credits

The General Laws of the Commonwealth of Massachusetts (the "Commonwealth") provide film tax credits that apply to Massachusetts income and excise taxes relating to expenditures incurred while making motion pictures in the Commonwealth. These film tax credits are transferable and are, therefore, available through purchase to any taxpayer in the Commonwealth.

The Company estimates the utilization of any remaining unused state tax credits by projecting the annual premium tax liability taking into account policy growth and rate changes, projecting future premium tax liability based on projected premium, tax rates and tax credits, and comparing projected future tax liability to the availability of remaining tax credits.

All of the Company's state tax credits are classified under Massachusetts law as transferable tax credits. All of the tax credits during 2018 were utilized against Massachusetts tax liabilities and are, therefore, admitted.

As of December 31, 2018 and 2017, the carrying value of the Massachusetts tax credits applied to related tax liabilities was \$2,231 and \$19,880, respectively. As of December 31, 2018 the Company did not have any unapplied Massachusetts tax credits. As of December 31, 2017 the Company had unapplied Massachusetts tax credits of \$3,933.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

9. Surplus

The NAIC has imposed regulatory risk-based capital ("RBC") requirements on health insurance companies, including the Company. The RBC calculation serves as a benchmark for the regulation of health insurance companies' solvency by state insurance regulators. At December 31, 2018 and 2017, the Company's total adjusted capital is in excess of the regulatory RBC requirements.

M.G.L. Chapter 141, which applies requirements of unfair insurance competition under Chapter 176D to HMOs and HMOs operated as a line of business, requires an HMO to have adjusted net worth of \$1,500 when initially licensed. Thereafter, an HMO must maintain a minimum adjusted net worth in an amount determined by the DOI based initially on a sliding scale over a seven-year phase-in period effective December 31, 2004. HMOs must maintain a minimum deposit of at least \$1,000 with a trustee acceptable to the DOI. The Company exceeded all regulatory Chapter 141 requirements at December 31, 2018 and 2017.

As a condition of granting an HMO license to HMO Blue, the DOI required the Companies to enter into an agreement with the DOI granting the DOI discretionary authority to require either company to issue a surplus note to the other company if either of the company's health RBC is significantly higher than the other company's RBC.

In December 2017, the Company invested in a surplus note in the amount of \$285,000 that was issued by BCBSMA in exchange for cash. The term of the note is 10 years at an interest rate of 2.95% and pays interest annually, commencing on September 30, 2018.

Each payment of interest and principal of the surplus notes may be made after obtaining prior written approval of the Massachusetts Commissioner of Insurance. Subject to payment restrictions, the note may be prepaid in whole at any time, or in part from time to time, without penalty and with interest due on the date of payment.

During September 2018, and after receiving approval from the Commissioner of the Massachusetts Division of Insurance, BCBSMA paid HMO Blue \$6,609 in accrued interest on the surplus note. No principal payments were processed during 2018. As of December 31, 2018 and 2017 there were no unapproved interest or principal payments.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

9. Surplus (continued)

The indebtedness is subordinated to all other obligations of the Company, including but not limited to, claims of members, members' beneficiaries, providers and all other claims, including claims for indebtedness issued, incurred or guaranteed by the Company. This surplus note is not registered under the Securities Act of 1933 or distributed pursuant to Rule 144A under the Securities Act of 1933.

10. Permitted Statutory Accounting Practices

State insurance laws and regulations prescribe accounting practices for determining statutory net income and surplus for insurance companies. In addition, state regulators may permit statutory accounting practices that differ from prescribed practices. The Company had no permitted practices that would have an effect on statutory surplus at December 31, 2018 and 2017.

11. Related-Party Transactions

BCBSMA and HMO Blue (the "Companies") have an intercompany loan agreement which allows borrowings between the companies not to exceed the lesser of 3% of HMO Blue's admitted assets on a statutory basis or 25% of HMO Blue's net worth on a statutory basis calculated as of the previous year-end or if loans exceed the maximum amount per the calculation, by obtaining permission from the Massachusetts Insurance Commissioner of the Company's intent to exceed the limits. These loans bear interest based on the overnight LIBOR rate plus a spread or a fixed rate as agreed to by the Companies. During 2018, there were no intercompany borrowings between HMO Blue and BCBSMA.

As of December 31, 2018 and 2017, the Company had payables with BCBSMA of \$11,543 and \$18,908, respectively.

In 2008, BCBSMA and HMO Blue each committed to invest \$10,000 in BlueCross BlueShield Ventures, Inc. (the "General Partner") and BlueCross BlueShield Venture Partners, L.P. (the "Partnership"), in the form of 20 Class A shares of the General Partner and 17.1% limited interest in the Partnership. BCBS Venture is a strategic corporate venture fund formed by eleven Blue Cross and Blue Shield plans to invest in emerging companies that will bring greater innovation, efficiency, consumer-focus and transparency to healthcare.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

11. Related-Party Transactions (continued)

As of December 31, 2018, HMO Blue has contributed \$9,465 to the Partnership and \$100 to the General Partner. As of December 31, 2018, the Company had an outstanding contingent commitment for additional funding of \$435 related to the future equity contributions in the Partnership. As of December 31, 2018 and 2017, the admitted book values of the company's investment in BCBS Venture were \$7,484 and \$7,129, respectively.

In 2011, the Companies each committed to invest \$10,000 in BlueCross BlueShield Ventures II, Inc. (the "General Partner II") and BlueCross BlueShield Venture Partners II, L.P. (the "Partnership II"), in the form of 200 Class A shares of the General Partner II and 10.5% limited interest in the Partnership II. BCBS Venture II is a strategic corporate venture fund formed by twenty Blue Cross and Blue Shield plans to primarily make equity investments in emerging companies of strategic interest to Blue Plans while pursuing positive financial returns.

As of December 31, 2018, HMO Blue has contributed \$8,468 to the Partnership II and \$100 to the General Partner II. As of December 31, 2018, the Company had an outstanding contingent commitment for additional funding of \$1,432 related to the future equity contributions in the Partnership II. As of December 31, 2018 and 2017, the admitted book values of the company's investment in BCBS Venture II were \$7,136 and \$7,293, respectively.

There were no non-admitted assets related to the Company's investments in Subsidiary, Controlled, and Affiliated Entities as of December 31, 2018 and 2017.

HMO Blue and BCBSMA operate under common Board of Directors management and control. The Company participates in a bilateral intercompany agreement with BCBSMA to settle any claims, fees, administrative cost expense allocation, and pass-through cash and expenses paid by one company on behalf of the other company.

Under the terms of its license with Blue Cross and Blue Shield Association, BCBSMA has also entered into a unilateral agreement with HMO Blue to guarantee all current and future financial obligations of HMO Blue.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

11. Related-Party Transactions (continued)

HMO Blue and BCBSMA have an undivided interest in property and equipment. The apportionment of fixed assets is allocated to each company based on a rolling five-year average of pro-rata administrative expenses. Depreciation expenses are charged to each company based on utilization.

Employees of the Companies (the "Associates") are either: concurrently employed by the Companies or solely employed by BCBSMA or employed under a Tri-Party Agreement between BCBSMA, HMO Blue and Indigo Insurance Services, LLC. ("Indigo") a subsidiary of Zaffre Investments, LLC.

Individuals solely employed by BCBSMA include senior level management ("SLM") and non SLM individuals who provide routine services that benefit specific products, programs, and subsidiaries of BCBSMA. The compensation, benefits and administrative expenses of the concurrently employed Associates are charged to the Companies in accordance with their provision of services to each company.

For the individuals solely employed by BCBSMA, the pro-rata portion of compensation, benefits and administrative expenses attributable to the services provided to HMO Blue is charged to HMO Blue on an arm's length basis, including a mark-up. A common paymaster arrangement has been established for payroll and payroll related benefits. An agency arrangement has been established for payment of claims and operating expenses and receipt of funds. The Companies' pension and post-retirement benefits plans ("Benefit Plans") are sponsored by BCBSMA and BCBSMA is liable for the Benefit Plans. BCBSMA charges HMO Blue, as a participating employer of the Benefit Plans, a fee based on HMO Blue's allocated share of the Benefit Plans' expenses.

12. Retrospectively Rated Contracts and Contracts Subject to Redetermination

The Company receives premium payments from the Centers for Medicare & Medicaid Services ("CMS") on a monthly basis to provide comprehensive healthcare benefits for the Company's insured Medicare members. Premiums are fixed during the contract period, however, are subject to retroactive risk adjustments based on submitted diagnosis data accepted by CMS throughout the year. The Company estimates retroactive risk adjustment revenue based on accepted data and its adjusted risk scores. This revenue is recognized when the amounts become determinable and collectability is reasonably assured.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

12. Retrospectively Rated Contracts and Contracts Subject to Redetermination (continued)

The total amount of net premiums written by the Company that are subject to retrospective rating features was \$505,537 and \$486,156 for the years ended December 31, 2018 and 2017, respectively, which represents approximately 10%, respectively, of Company's written premiums for both 2018 and 2017. No other premiums written by the Company are subject to retrospective rating features.

13. Risk-Sharing Provisions of the ACA

As discussed in Note 2, the Company wrote accident and health insurance premium that is subject to the ACA risk-sharing provisions. The ACA risk-sharing provisions had an impact on admitted assets, liabilities, and revenue for the current and prior year, and were as follows:

	December 31, 2018				2018				
	Rec	eivable	(]	Payable)	I	ncome	(Expense)		Ref (1)
a. Permanent ACA risk adjustment program				_					
Premium adjustments	\$	200	\$	(9,500)	\$	_	\$	(20,284)	(a)
Risk adjustment user fees		_		(400)		_		(726)	(f)
Subtotal ACA permanent risk adjustment program		200		(9,900)				(21,010)	
b. Transitional ACA reinsurance program									
Claims paid		_		_		1,101		_	(b)
Claims unpaid		_		_		_		_	(g)
Related to uninsured plans		_		_		_		_	(g)
Contributions – not reported as ceded premium		_		_		_		_	(c) (d)
Ceded reinsurance premiums		_				_		_	(e)
Subtotal ACA transitional reinsurance program		_		_		1,101		_	
c. Temporary ACA risk corridor program									
Accrued retrospective premium		_		_		_		_	(h)
Reserve for rate credits or policy experience									
rating refunds		_				_		_	(h)
Subtotal ACA risk corridors program						_		_	
d. Total for ACA risk sharing provisions	\$	200	\$	(9,900)	\$	1,101	\$	(21,010)	

Ref (1):

- (a) This receivable has been admitted.
- (b) This recoverable has been admitted.
- (c) There were no reinsurance contributions (not reported as ceded premium) as of December 31, 2018.
- (d) This expense was recorded within administrative expenses.
- (e) There were no ceded reinsurance premiums paid in 2018.
- (f) At December 31, 2018, risk adjustment user fee payable adjustments were \$(400) and \$(326) related to benefit years 2016 and 2017, respectively, and were based on most recent CMS notice received in 2018.
- (g) No balances or premium was excluded from the ACA Reinsurance Program.
- (h) No balances or premium was excluded from the ACA Risk Corridor Program.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

13. Risk-Sharing Provisions of the ACA (continued)

	December 31, 2017				2017				
	Re	ceivable	(F	Payable)	Income	(]	Expense)	Ref (1)	
a. Permanent ACA risk adjustment program									
Premium adjustments	\$	14,550	\$	_	\$ _	\$	(11,044)	(a)	
Risk adjustment user fees		_		(245)	_		(486)	(f)	
Subtotal ACA permanent risk adjustment program		14,550		(245)	 _		(11,530)		
b. Transitional ACA reinsurance program									
Claims paid		1,715		_	5,002		_	(b)	
Claims unpaid		_		_	_		_	(g)	
Related to uninsured plans		_		_	_		_	(g)	
Contributions – not reported as ceded premium		_		_	_		_	(c) (d)	
Ceded reinsurance premiums		_		_	_		_	(e)	
Subtotal ACA transitional reinsurance program		1,715			5,002		_	<u>.</u>	
c. Temporary ACA risk corridor program									
Accrued retrospective premium		_		_	_		_	(h)	
Reserve for rate credits or policy experience									
rating refunds		_		_	_		_	(h)	
Subtotal ACA risk corridors program		_		_	_		_		
d. Total for ACA risk sharing provisions	\$	16,265	\$	(245)	\$ 5,002	\$	(11,530)		

Ref (1):

- (a) This receivable has been admitted.
- (b) This recoverable has been admitted.
- (c) There were no reinsurance contributions (not reported as ceded premium) as of December 31, 2017.
- (d) This expense was recorded within administrative expenses.
- (e) There were no ceded reinsurance premiums paid in 2017.
- (f) At December 31, 2017, risk adjustment user fee payable adjustments were \$(245) and \$(241) related to benefit years 2016 and 2015, respectively, and were based on most recent CMS notice received in 2017.
- (g) No balances or premium was excluded from the ACA Reinsurance Program.
- (h) No balances or premium was excluded from the ACA Risk Corridor Program.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

13. Risk-Sharing Provisions of the ACA (continued)

			Roll-I	Forward	d of Prior Y	Year ACA I	Risk Sha	ring Balance	es		
	Accru	ıed	Received	/Paid	Differe	ences	Adju	stments		Unsettled	
	Rec	(Pay)	Rec	(Pay)	Rec	(Pay)	Rec	(Pay)	Ref (3)	Rec	(Pay)
a. Permanent ACA risk											
adjustment											
Premium adjustments receivable	\$ 14,550	\$ -	\$ 3,566	\$ -	\$10,984	\$ - \$	_	\$(10,784)	(a)	\$ 200	\$ -
Premium adjustments (payable)		_	_	_	_				(b)	_	
Subtotal ACA permanent risk adjustment program	14,550	_	3,566	_	10,984	_	_	(10,784)		200	_
b. Transitional ACA reinsurance											
Claims paid	1,715	_	2,816	_	(1,101)	_	_	1,101	(c)	_	_
Claims unpaid	_	_	_	_	_	_	_	_	(d)	_	_
Related to uninsured plans	_	_	_	_	_	_	_	_		_	_
Contributions – not reported as ceded premium	_	_	_	_	_	_	_	_		_	_
Ceded reinsurance premiums	_	_	_	_	_	_	_	_		_	_
Subtotal ACA transitional reinsurance program	1,715	_	2,816	_	(1,101)	_	_	1,101		_	_
c. Temporary ACA risk corridor											
Accrued retrospective premium	_	_	_	_	_	_	_	_		_	_
Reserve for rate credits or											
policy experience	_	_	_	_	_	_	_	_		_	_
rating refunds		_	_	_	_	_	_	_		_	
Subtotal ACA risk corridors program	_	_	_	_	_	_	_	_		_	_
d. Total for ACA risk sharing provisions	\$ 16,265	\$ -	\$ 6,382	\$ -	\$ 9,883	\$ - \$	_	\$ (9,683)		\$ 200	\$ -

Ref (3):

As of December 31, 2018 and 2017, the Company did not report any risk-sharing provisions related to the temporary ACA Risk Corridor Program. Therefore, no risk-corridor related asset or liability balances were either accrued, impaired or non-admitted.

⁽a) Adjustments to the prior benefit year ACA Risk Adjustment received in 2018 were \$10,784 (gross of non-admitted) and were based on the reconsideration settlement notice from the Commonwealth of Massachusetts Health Insurance Connector Authority.

⁽b) Adjustments to the prior benefit year ACA Risk Adjustment payable in 2018 was \$0.

⁽c) The adjustment for amounts recoverable for claims paid under the Transitional ACA Reinsurance Program was \$1,101 and reflects the differences between previously estimated amounts and the final settlement notice received.

⁽d) The adjustment for amounts recoverable for claims unpaid under the Transitional ACA Reinsurance Program was \$0 and reflects the differences between previously estimated amounts and the final settlement notice received.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

14. Health Care Receivables

Amounts receivable for pharmaceutical rebates are estimated based on a per script calculation. Rebate amounts are typically paid on a quarterly basis 150 days after the end of each quarter. The Company's pharmacy rebate receivable balances are as follows:

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements		Rel Bi Ot	armacy bates as illed or herwise nfirmed	Red Rec Wi	etual bates eived ithin Days	Red Rec Withi	tual bates eived in 91 to days	Red Rec Wi More	tual pates eived thin e Than Days
12/31/2018	\$	4,658	\$	4,490	\$	_	\$	_	\$	_
9/30/2018		4,656		4,388		_		_		_
6/30/2018		4,380		4,133		_		4,355		_
3/31/2018		4,568		3,568		-		4,062		57
12/31/2017		3,657		3,628		_		3,505		89
9/30/2017		3,715		3,579		_		3,435		259
6/30/2017		2,900		2,902		_		3,514		102
3/31/2017		2,408		2,384		_		3,325		60
12/31/2016		2,384		2,487		_		2,790		50
9/30/2016		2,433		2,305		_		2,792		89
6/30/2016		2,598		2,616		_		2,739		47
3/31/2016		2,383		1,150		_		2,757		210

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

14. Health Care Receivables (continued)

The Company's risk sharing receivable balances are as follows:

<u>Y</u> ear	Evaluation Period Year Ending	Re as l	Risk Sharing eceivable Estimated in the rior Year	Rec	Risk Sharing eeivable as stimated in the erent Year	Risk Sharing Receivable Billed	Sh Rec	Risk aring eivable et Billed	Sh An Rec	ual Risk naring nounts eived in r Billed	R Sha Ame Recei	tual isk aring ounts ived in irst After	Ri Sha Amo Recei Sec	tual isk ring ounts ved in ond After	Act Ris Shar Amo Recei All O	sk ring unts ved –
2018	2018 2019	\$	33,695	\$	19,158 6,831	\$ 15,610 35	\$	3,548 6,796	\$	15,610 35		- -	\$	_ _	\$	_
2017	2017 2018		8,621 N/A		12,779 33,695	9,878 93		36,602		9,878 -		2,901		_ _		_
2016	2016 2017		17,351 N/A		56,332 8,621	47,395 N/A		8,936 N/A		19,952 N/A		18,507 N/A		– N/A		N/A

15. Leases

The Companies jointly have a long-term operating lease agreement for 347,618 square feet for its corporate headquarters on Huntington Avenue in Boston, Massachusetts. Occupancy and rental expense commenced April 2015 and will continue for 15 years 2 months, with options to extend for up to 10 years thereafter. Additionally, the Companies jointly occupy space through three smaller, long-term, non-cancelable, operating lease agreements for office and data center facilities, which extend through various dates through 2024.

The Companies sublease a portion of its headquarters through a December 2016 – May 2020 non-cancelable sublease agreement for 34,417 square feet of space, for which \$1,566 of rental payments were received in 2018, with additional monthly installments of \$130 to be received through April 2020.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

15. Leases (continued)

In October 2018 the Companies entered into an additional non-cancelable sublease agreement extending through April 2030 for 43,598 square feet. Occupancy and monthly rental payments of \$185, increasing annually, will commence in 2019. The aggregate future minimum rentals to be received from these agreements is \$28,944. The Companies also sublease approximately 9,300 square feet of space through various smaller, primarily month-to-month, arrangements.

For 2018 and 2017, the Company recorded rental expenses of \$5,925 and \$5,891, respectively, of which, \$5,816 and \$5,785 were related to office space rental expenses, respectively.

At December 31, 2018, allocated minimum rental commitments on significant non-cancelable operating leases for the Company are as follows:

2019	\$ 6,477
2020	6,511
2021	6,564
2022	6,579
2023	6,595
Thereafter	42,431

In addition, the Company has agreements with outside vendors to provide certain information technology services for a significant portion of the Company's business operations. The Company's minimum commitments under these agreements vary annually, with amounts ranging from \$6,432 to \$4,012 per year from 2019 through 2021.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

16. Debt

The Company does not have any outstanding capital note obligations in its financial statements as of December 31, 2018.

The Companies jointly entered into three revolving credit agreements. Borrowings under these unsecured lines of credit bear interest on a fixed or floating interest rate basis.

The first facility for \$200,000 matured in June 2018 and was renewed until June 2019. The second facility for \$50,000 matured in June 2018 and was renewed until June 2019. The third facility for \$50,000 matured in October 2018 and was renewed until October 2019.

At December 31, 2018 the Company had no principal or accrued interest outstanding and accrued fees of \$1. At December 31, 2017, the Company had \$150,000 in outstanding principal under these facilities which was paid in 2018. During 2018 and 2017, the Company paid interest of \$642 and \$47 and fees of \$274 and \$244, respectively on these facilities. As a covenant of the first facility, the borrowers are required to certify compliance on an annual basis of a minimum Risk-Based Capital level of 300% of Company Action Level and are required to certify compliance on a quarterly basis that the Cash Reserve Ratio is not less than 1.25 to 1.0. As a covenant of the second and third facilities, the borrowers are required to maintain at all times a combined liquidity of not less than \$1,250,000. As of December 31, 2018, there were no violations of the debt terms and covenants reported.

In October 2014, the Companies jointly entered into a \$150,000 5-year unsecured term loan which amortizes monthly and has a fixed interest rate of 2.35%. The Companies are required to certify compliance on an annual basis of a minimum Risk-Based Capital level of 300% of Company Action Level and a Cash Reserve Ratio is not less than 1.25 to 1.00. The Companies each received proceeds from the term loan of \$75,000. In 2018, HMO Blue paid principal of \$15,000 and interest of \$494. At December 31, 2018, HMO Blue has a carrying value outstanding of \$12,500 and accrued interest of \$1. As of December 31, 2018, there were no violations of the debt terms and covenants reported.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

16. Debt (continued)

In March 2017, the Companies jointly entered into a \$100,000 5-year unsecured term loan which amortizes monthly and has a fixed interest rate of 2.79%. The Companies are required to certify compliance on an annual basis of a minimum Risk-Based Capital level of 350% of Company Action Level and a Cash Reserve Ratio is not less than 1.25 to 1.00. The Companies each received proceeds from the term loan of \$50,000. In 2018, HMO Blue paid principal of \$10,000 and interest of \$1,078. At December 31, 2018, HMO Blue has a carrying value of \$32,500 outstanding and accrued interest of \$3. As of December 31, 2018, there were no violations of the debt terms and covenants reported.

As of December 31, 2018, the combined aggregate amount of long-term borrowing maturities for each of the next five years are as follows:

Debt - Long-Term Borrowings	HMO Blue
Maturing in 2019	22,500
Maturing in 2020 ^(a)	110,000
Maturing in 2021	10,000
Maturing in 2022	2,500
Maturing in 2023	_
Total Maturities	145,000
(a) Includes \$100,000 in five-year term borrowings from FHLB.	-

17. FHLB Agreements

The Company is a member of the FHLB of Boston. Through its membership, the Company has conducted business activity (borrowings) with the FHLB. It is part of the Company's strategy to utilize these funds as back-up liquidity and to ensure sufficient capital and credit to meet operational needs and provide financial flexibility to respond to strategic opportunities in the marketplace.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

17. FHLB Agreements (continued)

The Company has determined the actual maximum borrowing capacity as \$100,000. The Company based this amount on anticipated borrowing needs of the Company.

As a requirement of the FHLB membership, the Company has \$2,101 and \$1,875 of FHLB Class B Membership Stock at December 31, 2018 and 2017, respectively. The Class B Membership Stock is not eligible for redemption. In addition, the Company is required to purchase FHLB Activity Stock up to 4.0% of the value of principal borrowed which was reduced from 4.5% as of December 31, 2017. At December 31, 2018 and 2017, the Company recorded \$4,000 and \$4,500 of FHLB Activity Stock, respectively.

At December 31, 2018, the Company had outstanding borrowings of \$50,000 for a 5-year term at a rate of 1.60% which matures in 2020 and a second outstanding borrowing of \$50,000 for a 5-year term at a rate of 2.05% which matures in 2020. During the 2018 and 2017 periods, the Company paid \$1,850 in interest expense. At December 31, 2018 and 2017, the Company had outstanding principal of \$100,000 and accrued interest of \$157.

The Company is required to pledge collateral for all outstanding borrowings with the FHLB which consists of U.S. Government backed securities which are valued at 96% for maturities under 3 years and 94% for maturities over 3 years and FNMA & FHLMC mortgage-backed securities which are valued at 92% of current market value.

The total collateral pledged against these borrowings had a fair value as of December 31, 2018 and 2017, of \$112,388 and \$111,418, respectively, and a carrying value of \$114,191 and \$112,150, respectively. The maximum amounts pledged during the 2018 and 2017 reporting periods had a fair value of \$113,622 and \$112,542 and a carrying value of \$115,490 and \$112,802, respectively. The Company has no prepayment obligations with the FHLB.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

18. Commitments and Contingencies

As of December 31, 2018, the Company's remaining commitments, pursuant to the terms of the investment agreements, are as follows:

Blue Cross Blue Shield Venture Partners, L.P.	\$ 435
Blue Cross Blue Shield Venture Partners II, L.P.	1,432
Blue Cross Blue Shield Venture Partners III, LLC.	1,637
Hancock Capital Partners V, L.P.	1,665
Comvest Capital III, L.P.	4,002
Park Square Capital Credit Opp II Feeder, L.P.	6,194
Comvest Capital IV, L.P.	13,431
New Mountain Net Lease, LP.	8,834
Park Square Capital Credit Opp III Feeder, L.P.	16,659
Total Commitments	\$ 54,289

The Company is involved in pending and threatened litigation of the character incidental to its business or arising out of its insurance operations, and is, from time to time, involved as a party in various governmental and administrative proceedings. Management continues to monitor these matters, and believes the Company has accrued adequate reserves against potential liabilities.

The Company and all other Blue Plans have been named as defendants in antitrust class-action complaints that have been brought against the Blue Plans and the Blue Cross and Blue Shield Association ("BCBSA"); these cases have been consolidated in a multidistrict litigation pending in Federal Court in Alabama. The plaintiffs, who include both providers and Plan subscribers, assert that they have been damaged as a result of alleged anticompetitive conduct. Their claims focus on, among other things, BCBSA's 'exclusive service area' requirement, 'best efforts' rules (limiting revenue from non-Blue business), alleged restrictions on Plans' ability to transfer ownership interests, and rules governing the BlueCard program. The Company is vigorously defending against these claims, as are BCBSA and the other Blue Plans. The court has not yet set dates for any trials.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

18. Commitments and Contingencies (continued)

Given the status of the litigation, an ultimate outcome cannot be presently determined or predicted by the Company. As of December 31, 2018, the date of the financial statements, the chance of future events confirming the fact of the loss or incurrence of a liability is reasonably possible and the Company has not accrued a contingent loss related to the litigation. The Company continues to vigorously defend these class actions.

19. State Assessments

In 2018, BCBSMA and HMO were obligated to pay three major assessments. The first is with the Commonwealth of Massachusetts' "Center for Health Information and Analysis" ("CHIA"). This is an administrative-type surcharge to cover state operating expenses. In the first quarter of 2018, the second of two HMO Blue payments of \$1,021 was made for the CHIA FY2018 assessment. HMO Blue's assessment to cover CHIA's FY2019 operations was \$1,849, which was paid in two installments during the fourth quarter of 2018.

The second is the Commonwealth of Massachusetts Health Policy Commission's assessment pursuant to Section 958 Chapter 9.04, "Assessment on Certain Health Care Provider and Surcharge Payors". This amount is based on the assessment percentage of the Company and the annual legislatively approved budget of the Health Policy Commission for FY2019. HMO Blue's portion of the FY2019 assessment is \$586. The first installment of \$295 was paid in December 2018 and the second payment of \$290 will be paid February 2019.

The third is the Commonwealth of Massachusetts' DOI "Health Care Assess Bureau" ("HCAB") assessment to pay for HCAB expenses. This assessment is based on the Company's portion of health premiums as reported to the HCAB. During the first quarter of 2018, HMO Blue paid \$308 to the HCAB for the FY2015 assessment which was based on FY2013 reported premium data. During the second quarter of 2018, HMO Blue paid \$428 to the HCAB for the FY2018 assessment which was based on FY2016 reported premium data.

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

20. ACA Insurer Fee

The Company is subject to an annual health insurance industry fee under section 9010 of the federal ACA. The ACA fee is allocated to individual health insurers based on the ratio of the entity's net premiums written to the amount of health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due.

The Consolidated Appropriations Act of 2016, Title II, § 201, Moratorium on Annual Fee on Health Insurance Providers ("HIPF"), has suspended collection of the HIPF or ACA fee for the 2017 calendar year. Therefore, there was no payment in the 2017 fee year.

As of December 31, 2017, the Company had written health insurance that was subject to the ACA and expected to conduct health insurance business in 2018. The Company's portion of the annual fee for the 2017 data year was \$47,969 and was paid in September 2018. This amount was reflected in the December 2017 special surplus and would have had a 23% impact on the Company's 2017 risk based capital ("RBC") and would not have triggered an RBC action level.


Enacted on January 22, 2018, along with continuing resolution legislation, H.R. 195, Division D – *Suspension of Certain Health-Related Taxes*, *§* 4003, suspends collection of the fee for the 2019 calendar year only. As of December 31, 2018 the Company did not have an annual health insurance industry fee reflected in special surplus and no payment will be due in the 2019 fee year based on the 2018 data year.

			2017
ACA fee assessment payable for the upcoming year	\$	- \$	48,717
ACA fee assessment paid	4	7,969	_
Premium written subject to ACA 9010 assessment	5,08	5,434	4,808,793
Total adjusted capital before surplus adjustment	1,41	3,755	1,383,664
Total adjusted capital after surplus adjustment	1,41	3,755	1,334,947
Authorized control level after surplus adjustment	22	5,530	213,071

Notes to Statutory-Basis Financial Statements (continued) (Dollars in Thousands)

21. Subsequent Events

The Company's management evaluated subsequent events through April 26, 2019, the date the financial statements were available to be issued.





working world

Ernst & Young LLP Tel: +1 617 266 2000 200 Clarendon Street Fax: +1 617 266 5843 Boston, MA 02116 ey.com

Report of Independent Auditors on Supplementary Information

The Board of Directors
Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc.

We have audited, in accordance with auditing standards generally accepted in the United States, the statutory-basis financial statements of Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. as of December 31, 2018, and for the year then ended, and have issued an adverse opinion with respect to conformity with U.S. generally accepted accounting principles and an unmodified opinion with respect to conformity with accounting practices prescribed or permitted by the Commonwealth of Massachusetts Division of Insurance thereon dated April 26, 2019. Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying supplemental investment disclosures are presented to comply with the National Association of Insurance Commissioners' Annual Statement Instructions and the National Association of Insurance Commissioners' Accounting Practices and Procedures Manual and for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the statutory-basis financial statements as a whole.

This report is intended solely for the information and use of the Company and state insurance departments to whose jurisdiction the Company is subject and is not intended to be and should not be used by anyone other than these specified parties.

Ernst + Young LLP

April 26, 2019

Investment Risk Interrogatories – Statutory-Basis (Dollars in Thousands)

December 31, 2018

- 1. Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc.'s total admitted assets as reported on page two of its Annual Statement are \$2,266,462.
- 2. Following are the ten largest exposures to a single issuer/borrower/investment, excluding: (i) U.S. government, U.S. government agency securities and those U.S. government money market funds listed in the Appendix to the SVO Practices and Procedures Manual as exempt, (ii) property occupied by Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc. and (iii) policy loans:

Issuer	Description of Exposure	Amount	Percentage of Total Admitted Assets
BCBSMA Surplus Note	Other invested asset	\$ 280,749	12.387%
PIMCO All Asset Institutional Fund	Common stock	127,283	5.616
Lazard Asset Management Fund	Other invested asset	83,934	3.703
Primus HY Bond Fund	Other invested asset	73,874	3.259
BlueRock Market Neutral Fund LP	Other invested asset	64,591	2.850
RREEFF II Core REIT	Common Stock	60,902	2.687
Putnam Total Return Fund LLC	Other invested asset	59,404	2.621
Newton Global Equity Income Fund	Other invested asset	57,083	2.519
Beachpoint HY Bond Offshore Fund	Other invested asset	52,541	2.318
Parametric Portfolio Assoc LLC	Other Invested asset	48,281	2.130

3. Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc.'s total admitted assets held in bonds, short-term investments and preferred stock, by NAIC rating, are:

Bonds an	nd Short-Te	erm Invest	ments	Preferred Stock					
NAIC Rating	4	Amount		NAIC Rating	Am	Percentage of Total Admitted Assets			
NAIC 1	Ф	021 040	26.2610/	D/DD 1	φ.		0/		
NAIC-1	\$	821,840	36.261%	P/RP-1	\$	_	%		
NAIC-2		74,430	3.284	P/RP-2		_	_		
NAIC-3		2,404	0.106	P/RP-3		_	_		
NAIC-4		_	_	P/RP-4		_	_		
NAIC-5		_	_	P/RP-5		_	_		
NAIC-6		_	_	P/RP-6		_	_		
	\$	898,674	-		\$	_	_		

Investment Risk Interrogatories – Statutory-Basis (continued) (Dollars in Thousands)

4. Assets held in foreign investments:

		Percentage of Total
	Amount	Admitted Assets
Total admitted assets held in foreign investments	\$ 98,341	4.339%

5. Aggregate foreign investment exposure categorized by NAIC sovereign rating:

		Percentage of Total Admitted
NAIC Sovereign Rating	Amount	Assets
Countries rated NAIC-1	\$ 62,845	2.773%
Countries rated NAIC-2 Countries rated NAIC 3 or below	9,862 25,634	0.435 1.131

6. Largest foreign investment exposure by country, categorized by the country's NAIC sovereign rating:

NATOG - D. II		Percentage of Total Admitted
NAIC Sovereign Rating	Amount	Assets
Countries rated NAIC-1:		
United Kingdom	\$ 6,699	0.296%
Cayman Islands	24,377	1.076
Countries rated NAIC-2:		
United Kingdom	1,946	0.086
France	2,305	0.102
Countries rated NAIC-3:		
Guernsey	25,634	1.131

Investment Risk Interrogatories – Statutory-Basis (continued) (Dollars in Thousands)

- 7. The Company has no unhedged foreign currency exposure.
- 8. The Company has no aggregate unhedged foreign currency exposure.
- 9. The Company has no unhedged foreign currency exposures to a single country.
- 10. Ten largest non-sovereign (i.e., non-government) foreign issues:

	NAIC		Percentage of Total Admitted
lssuer	Rating	Amount	Assets
Park Square Cap Credit Oppty II Feeder	OIA	\$ 19,813	0.874%
Park Square Cap Credit Oppty III Feeder	OIA	5,821	0.257
HSBC HLDGS PLC	1FE	2,750	0.121
Sparebank 1 Boligkreditt 144A	1FE	2,664	0.118
UBS Group FDG Switz AG	1FE	2,582	0.114
Carlyle Global M 4a a1rr 144a	1FE	2,360	0.104
Sumitomo Mitsui Finl Group INC	1FE	2,347	0.104
AMMC CLO XI LTD 2012-11R2	1FE	2,343	0.103
GE Capital International FDG	1FE	2,291	0.101
Stadshypotek AB 144A	1FE	2,285	0.101

- 11. The Company has no assets held in Canadian investments greater than 2.5% of the Company's total admitted assets.
- 12. The Company has no assets held in investments with contractual sales restrictions.

Investment Risk Interrogatories – Statutory-Basis (continued) (Dollars in Thousands)

13. Amounts and percentages of admitted assets held in the ten largest equity interests:

		Percentage of Total
Name of Issuer	Amount	Admitted Assets
BCBSMA Surplus Note	\$ 280,749	12.387%
PIMCO All Asset Institutional Fund	127,284	5.616
Lazard Asset Management Fund	83,934	3.703
Primus High Yield Bond Fund	73,874	3.259
Blue Rock Market Neutral Fund LP	64,591	2.850
RREEFF III Core REIT	60,902	2.687
Putnam Total Return Fund LLC	59,404	2.621
Newton Global Equity Income Fund	57,083	2.519
Beachpoint High Yield Offshore Fund	52,541	2.318
Parametric Defensive Equity Fund	48,281	2.130

- 14. The Company has no assets held in nonaffiliated, privately placed equities greater than 2.5% of the Company's total admitted assets.
- 15. The Company has no assets held in general partnership interests greater than 2.5% of the Company's total admitted assets.
- 16. The Company has no mortgage loans greater than 2.5% of the Company's total admitted assets.
- 17. The Company has no aggregate mortgage loans that are greater than 2.5% of the Company's total admitted assets.
- 18. The Company has no assets held in real estate reported greater than 2.5% of the Company's total admitted assets, excluding home office properties.

Investment Risk Interrogatories – Statutory-Basis (continued) (Dollars in Thousands)

- 19. The Company has no assets held in investments held in mezzanine real estate loans greater than 2.5% of the Company's total admitted assets.
- 20. The Company has no securities lending or repurchase agreements during 2018.
- 21. The Company has no warrants not attached to other financial instruments, options, caps, and floors during 2018.
- 22. The Company has no potential exposure for collars, swaps, and forwards during 2018.
- 23. The Company had no potential exposure for future contracts during 2018.

Summary of Investment Schedule – Statutory-Basis (Dollars in Thousands)

December 31, 2018

			Admitted Assets as			
		Gro		Reported in		
_		Investment Holdings*		Annual Statement		
Investment Categories		Amount	Percentage	Amount	Percentage	
Donda						
Bonds: U.S. treasury securities	\$	227,719	10.586% \$	227,719	10.586%	
U.S. government agency and corporate obligations	Ф	221,119	10.360% ф	221,119	10.360%	
(excluding mortgage-backed securities):						
Issued by U.S. government agencies		33,866	1.574	33,866	1.574	
		33,800	0.015	333	0.015	
Issued by U.S. government-sponsored agencies		333	0.015	333	0.015	
Non-US government (including Canada, excluding		2 275	0.152	2 275	0.152	
mortgage backed securities)		3,275	0.152	3,275	0.152	
Securities issued by states, territories, and						
possessions and their political subdivisions						
in the U.S.:						
State, territory and possessions –		700	0.027	700	0.027	
general obligations		788	0.037	788	0.037	
Political subdivisions of states, territories, and		012	0.020	012	0.020	
possessions – general obligations		812	0.038	812	0.038	
Revenue and assessment obligations		2,322	0.108	2,322	0.108	
Industrial development and similar obligations						
Mortgage-backed securities (includes residential and						
commercial MBS):						
Pass-through securities:		24.40	4 #0 6	24.40	4.50	
Issued or guaranteed by GNMA		34,106	1.586	34,106	1.586	
Issued or guaranteed by FNMA and FHLMC		181,640	8.444	181,640	8.444	
All other		_	_	_	_	
CMOs and REMICs:						
Issued or guaranteed by GNMA, FNMA,		= 0 -40		7 0 - 10		
FHLMC ,or VA		59,649	2.773	59,649	2.773	
Issued by non-U.S. Government issuers and						
collateralized by MBS issued or guaranteed						
by GNMA, FMNA, FHLMC, or VA		106	0.005	106	0.005	
All other		35,877	1.668	35,877	1.668	
Other debt and other fixed income securities						
(excluding short term):						
Unaffiliated domestic securities (includes credit						
tenant loans and hybrid securities)		233,042	10.834	233,042	10.834	
Unaffiliated Non- U.S. (including Canada)		77,764	3.615	77,764	3.615	
Affiliated securities		_	_	_	_	

Summary of Investment Schedule – Statutory-Basis (continued) (Dollars in Thousands)

		Gross			Admitted Assets as Reported in		
		Investment Holdings*			Annual Statement		
Investment Categories		Amount	Percentage		Amount	Percentage	
Equity interests:							
Investments in mutual funds	\$	204,473	9.506%	\$	204,473	9.506%	
Preferred stock:	Ψ	201,173	J.50070	Ψ	201,175	7.2 0070	
Affiliated		_	_		_	_	
Unaffiliated		_	_		_	_	
Publicly traded equity securities							
(excluding preferred stock):							
Affiliated		_	_		_	_	
Unaffiliated		_	_		_	_	
Other equity securities:							
Affiliated		270	0.013		270	0.013	
Unaffiliated		6,375	0.296		6,375	0.296	
Other equity interests including tangible		3,272	0.2>0		0,5 7 6	0.270	
personal property under lease:							
Affiliated		_	_		_	_	
Unaffiliated		_	_		_	_	
Mortgage loans:							
Construction and land development		_	_		_	_	
Agricultural		_	_		_	_	
Single family residential properties		_	_		_	_	
Multifamily residential properties		_	_		_	_	
Commercial loans		_	_		_	_	
Mezzanine real estate loans		_	_		_	_	
Real estate investments:							
Property occupied by company		88,433	4.111		88,433	4.111	
Property held for production of income (includes							
\$0 of property acquired in satisfaction of debt)		_	_		_	_	
Property held for sale (includes \$0 of property							
acquired in satisfaction of debt)		_	_		_	_	
Contract loans		_	_		_	_	
Receivables for securities		9,154	0.426		9,154	0.426	
Securities lending		_	_		_	_	
Cash, cash equivalents and short-term investments		29,154	1.355		29,154	1.355	
Other invested assets	_	921,886	42.858		921,886	42.858	
Total invested assets	\$	2,151,044	100.000%	\$	2,151,044	100.000%	
1 out III out wood	_						

^{*}Gross investment holdings as valued in compliance with NAIC Accounting Practices and Procedures Manual.

Note to Supplemental Investment Disclosures

December 31, 2018

Note-Basis of Presentation

The accompanying supplemental schedules present selected investment disclosures as of December 31, 2018, and for the year then ended for purposes of complying with the National Association of Insurance Commissioners' Accounting Practices and Procedures Manual and agree to or are included in the amounts reported in the Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc.'s 2018 Statutory Annual Statement as filed with the Commonwealth of Massachusetts Division of Insurance.

EY | Assurance | Tax | Transactions | Advisory

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

© 2019 Ernst & Young LLP. All Rights Reserved.

ey.com